Metronomic low dose temozolomide (TMZ): Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

17 May 2024

  • curprev 20:1220:12, 17 May 2024‎ Lazy talk contribs‎ 3,163 bytes +3,163‎ Created page with "{{TreatmentInfo |drug_name=Metronomic Low-Dose Temozolomide (TMZ) |FDA_approval=FDA-approved for glioblastoma but standard metronomic dosing is still under investigation |used_for=Glioblastoma Multiforme (GBM), recurrent GBM |clinical_trial_phase=Phase II and III for metronomic dosing schedules |common_side_effects=Nausea, vomiting, fatigue, myelosuppression, lymphopenia |OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis |OS_with=Studies..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Metronomic_low_dose_temozolomide_(TMZ)"